Today PaxVax announced it has entered into a definitive agreement to be acquired by US biotech firm Emergent BioSolutions (NYSE: EBS).
Emergent will acquire PaxVax’ portfolio of commercialized vaccines (Vaxchora and Vivotif for cholera and typhoid, respectively) and pipeline for diseases including adenovirus and chikungunya.
The all cash transaction, valued at $270 million, will create the world’s largest independent specialty vaccine company with global R&D, manufacturing and commercial operations - and will empower the public with better protection against a number of emerging health threats. .
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze